Low blood lymphocyte count at 30 days post transplant predicts worse acute GVHD and survival but not relapse in a large retrospective cohort

Z. Gul, E. Van Meter, M. Abidi, I. Ditah, M. Abdul-Hussein, A. Deol, L. Ayash, L. G. Lum, E. K. Waller, V. Ratanatharathorn, J. Uberti, Z. Al-Kadhimi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Multiple reports have shown that low absolute lymphocyte count at day 30 (ALC30) after allogeneic hematopoietic SCT (AHSCT) is associated with higher risk of disease relapse and worse OS. However, these reports included heterogeneous populations with different grafts and GVHD prophylaxis. Therefore, we retrospectively evaluated the association of ALC30 with transplant outcomes in a cohort of 381 consecutive patients who underwent AHSCT between 2005 and 2010 and received T-replete PBSC grafts and Tacrolimus/Mycophenolate combination as GVHD prophylaxis. Median follow-up was 57 months. Lower ALC30 (≤400 × 106/L) was associated with lower OS and increased nonrelapse mortality (NRM) for the whole cohort as well as for recipients of SD and UD grafts separately. Lower ALC30 was associated with more severe acute GVHD (aGVHD; III-IV) for the entire cohort as well as for the SD and UD groups. No association was found between lower ALC30 and relapse. Pretransplant factors associated with lower ALC30 were: unrelated donors; HLA mismatch; older donors; lower recipient age; and lower CD34+ cell dose. In this large retrospective study, ALC30≤400 × 106/L was associated with worse OS, increased NRM and severe aGVHD.

Original languageEnglish (US)
Pages (from-to)432-437
Number of pages6
JournalBone marrow transplantation
Volume50
Issue number3
DOIs
StatePublished - Mar 1 2015

Fingerprint

Lymphocyte Count
Transplants
Recurrence
Survival
Unrelated Donors
Mortality
Tacrolimus
Retrospective Studies
Tissue Donors
Population

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Low blood lymphocyte count at 30 days post transplant predicts worse acute GVHD and survival but not relapse in a large retrospective cohort. / Gul, Z.; Van Meter, E.; Abidi, M.; Ditah, I.; Abdul-Hussein, M.; Deol, A.; Ayash, L.; Lum, L. G.; Waller, E. K.; Ratanatharathorn, V.; Uberti, J.; Al-Kadhimi, Z.

In: Bone marrow transplantation, Vol. 50, No. 3, 01.03.2015, p. 432-437.

Research output: Contribution to journalArticle

Gul, Z, Van Meter, E, Abidi, M, Ditah, I, Abdul-Hussein, M, Deol, A, Ayash, L, Lum, LG, Waller, EK, Ratanatharathorn, V, Uberti, J & Al-Kadhimi, Z 2015, 'Low blood lymphocyte count at 30 days post transplant predicts worse acute GVHD and survival but not relapse in a large retrospective cohort', Bone marrow transplantation, vol. 50, no. 3, pp. 432-437. https://doi.org/10.1038/bmt.2014.284
Gul, Z. ; Van Meter, E. ; Abidi, M. ; Ditah, I. ; Abdul-Hussein, M. ; Deol, A. ; Ayash, L. ; Lum, L. G. ; Waller, E. K. ; Ratanatharathorn, V. ; Uberti, J. ; Al-Kadhimi, Z. / Low blood lymphocyte count at 30 days post transplant predicts worse acute GVHD and survival but not relapse in a large retrospective cohort. In: Bone marrow transplantation. 2015 ; Vol. 50, No. 3. pp. 432-437.
@article{ffe06dcedcdd452cbccae6dcd7854c06,
title = "Low blood lymphocyte count at 30 days post transplant predicts worse acute GVHD and survival but not relapse in a large retrospective cohort",
abstract = "Multiple reports have shown that low absolute lymphocyte count at day 30 (ALC30) after allogeneic hematopoietic SCT (AHSCT) is associated with higher risk of disease relapse and worse OS. However, these reports included heterogeneous populations with different grafts and GVHD prophylaxis. Therefore, we retrospectively evaluated the association of ALC30 with transplant outcomes in a cohort of 381 consecutive patients who underwent AHSCT between 2005 and 2010 and received T-replete PBSC grafts and Tacrolimus/Mycophenolate combination as GVHD prophylaxis. Median follow-up was 57 months. Lower ALC30 (≤400 × 106/L) was associated with lower OS and increased nonrelapse mortality (NRM) for the whole cohort as well as for recipients of SD and UD grafts separately. Lower ALC30 was associated with more severe acute GVHD (aGVHD; III-IV) for the entire cohort as well as for the SD and UD groups. No association was found between lower ALC30 and relapse. Pretransplant factors associated with lower ALC30 were: unrelated donors; HLA mismatch; older donors; lower recipient age; and lower CD34+ cell dose. In this large retrospective study, ALC30≤400 × 106/L was associated with worse OS, increased NRM and severe aGVHD.",
author = "Z. Gul and {Van Meter}, E. and M. Abidi and I. Ditah and M. Abdul-Hussein and A. Deol and L. Ayash and Lum, {L. G.} and Waller, {E. K.} and V. Ratanatharathorn and J. Uberti and Z. Al-Kadhimi",
year = "2015",
month = "3",
day = "1",
doi = "10.1038/bmt.2014.284",
language = "English (US)",
volume = "50",
pages = "432--437",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Low blood lymphocyte count at 30 days post transplant predicts worse acute GVHD and survival but not relapse in a large retrospective cohort

AU - Gul, Z.

AU - Van Meter, E.

AU - Abidi, M.

AU - Ditah, I.

AU - Abdul-Hussein, M.

AU - Deol, A.

AU - Ayash, L.

AU - Lum, L. G.

AU - Waller, E. K.

AU - Ratanatharathorn, V.

AU - Uberti, J.

AU - Al-Kadhimi, Z.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Multiple reports have shown that low absolute lymphocyte count at day 30 (ALC30) after allogeneic hematopoietic SCT (AHSCT) is associated with higher risk of disease relapse and worse OS. However, these reports included heterogeneous populations with different grafts and GVHD prophylaxis. Therefore, we retrospectively evaluated the association of ALC30 with transplant outcomes in a cohort of 381 consecutive patients who underwent AHSCT between 2005 and 2010 and received T-replete PBSC grafts and Tacrolimus/Mycophenolate combination as GVHD prophylaxis. Median follow-up was 57 months. Lower ALC30 (≤400 × 106/L) was associated with lower OS and increased nonrelapse mortality (NRM) for the whole cohort as well as for recipients of SD and UD grafts separately. Lower ALC30 was associated with more severe acute GVHD (aGVHD; III-IV) for the entire cohort as well as for the SD and UD groups. No association was found between lower ALC30 and relapse. Pretransplant factors associated with lower ALC30 were: unrelated donors; HLA mismatch; older donors; lower recipient age; and lower CD34+ cell dose. In this large retrospective study, ALC30≤400 × 106/L was associated with worse OS, increased NRM and severe aGVHD.

AB - Multiple reports have shown that low absolute lymphocyte count at day 30 (ALC30) after allogeneic hematopoietic SCT (AHSCT) is associated with higher risk of disease relapse and worse OS. However, these reports included heterogeneous populations with different grafts and GVHD prophylaxis. Therefore, we retrospectively evaluated the association of ALC30 with transplant outcomes in a cohort of 381 consecutive patients who underwent AHSCT between 2005 and 2010 and received T-replete PBSC grafts and Tacrolimus/Mycophenolate combination as GVHD prophylaxis. Median follow-up was 57 months. Lower ALC30 (≤400 × 106/L) was associated with lower OS and increased nonrelapse mortality (NRM) for the whole cohort as well as for recipients of SD and UD grafts separately. Lower ALC30 was associated with more severe acute GVHD (aGVHD; III-IV) for the entire cohort as well as for the SD and UD groups. No association was found between lower ALC30 and relapse. Pretransplant factors associated with lower ALC30 were: unrelated donors; HLA mismatch; older donors; lower recipient age; and lower CD34+ cell dose. In this large retrospective study, ALC30≤400 × 106/L was associated with worse OS, increased NRM and severe aGVHD.

UR - http://www.scopus.com/inward/record.url?scp=84938422827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938422827&partnerID=8YFLogxK

U2 - 10.1038/bmt.2014.284

DO - 10.1038/bmt.2014.284

M3 - Article

C2 - 25599169

AN - SCOPUS:84938422827

VL - 50

SP - 432

EP - 437

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -